Publications
View and download slide summaries of the latest original articles focusing on cytokine signalling therapies within rheumatoid arthritis. All materials produced by the CSF team are subsequently reviewed and approved by individual Steering Committee members.
August 2020
Eficácia e Segurança a Longo Prazo de Baricitinib com e sem Metotrexato para o Tratamento de Artrite Reumatoide: Experiência com a Continuação de Baricitinib Monoterapia ou Depois de Troca de Metotrexato Monoterapia ou Baricitinib mais Metotrexato
Arthritis Care Res (Hoboken) 2020;72(8):1112-1121
This 24-week update from the baricitinib RA-BEYOND LTE study follows patients previously treated in the pivotal study RA-BEGIN. It demonstrates the maintained safety and efficacy of baricitinib monotherapy, and the effects of concurrent MTX treatment on response rates and patient reported outcomes. Previous P3 study RA-BEGIN demonstrated the superior efficacy of 4mg baricitinib compared to MTX monotherapy up to 52 weeks, with no major safety events being identified. At the end of the trial, pati...